ARSACS and a SACS Carrier Result: What the Research Actually Shows

ARSACS and a SACS Carrier Result: What the Research Actually Shows

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: A consumer report that flags one changed copy of the SACS gene describes a carrier, meaning a person with one changed copy and one working copy. GeneReviews puts it flatly: “Heterozygotes are asymptomatic and are not at risk of developing the disorder”. Since 2024 that sentence has a measured backing. Two research teams, working apart, counted the sacsin protein in blood cells: near zero in people with two changed copies, and about half of normal in carriers who were well. Half is enough. What a carrier result does raise is a question about a future pregnancy, and that question has a real number as its answer.

What you’ll learn

• What one changed SACS copy does to sacsin levels, and how that became measurable in a blood draw in 2024
• The honest per-pregnancy number, why the Quebec carrier rates need their dates attached, and why a partner’s test settles it
• How results are confirmed in the US and Canada, and the one thing a consumer report is built not to see
• What is approved in 2026 (nothing), and the size problem that blocks gene therapy for this gene

Sacsin is one of the largest proteins the body builds, and half of it is enough

The SACS gene sits on chromosome 13, at a spot written as 13q12.12. It carries the recipe for a protein called sacsin. Sacsin is 4,579 amino acid units long and weighs about 521 kilodaltons, a unit of molecular mass. That makes it one of the largest proteins the human body builds.

What does it do? UniProt, the reference database for protein sequences, calls it a co-chaperone, meaning a helper that keeps other proteins folded the right way. Think of a safety inspector on a building crew. The inspector does not lay bricks. The inspector keeps the scaffolding from buckling.

Honesty matters here. MedlinePlus Genetics, the NIH consumer resource, still says the “specific function of the protein is unknown”. Research only “suggests that sacsin plays a role in organizing proteins into bundles called intermediate filaments”. A 2022 review agrees that sacsin does chaperone work. It may also matter for mitochondria, the parts of a cell that make energy. That review then ends with a plain admission: “Further studies are needed to define the exact functions of sacsin”. Twenty-six years after the gene was found, the job description is still being written.

Why nerve cells feel it first

Nerve cells stretch long wires called axons. Special filaments inside them set the size and shape of those wires. When sacsin is missing, those filaments clump. In a mouse model without sacsin, mitochondria failed to travel out to the far branches of Purkinje cells. Those large cells coordinate movement in the cerebellum. Calcium handling inside them went wrong too. That is animal data, not human data, and it should be read as a model rather than a fact about patients.

The number a carrier is actually holding

In July 2024, a team writing in Brain Communications reported something new. They measured sacsin directly in white blood cells drawn from a vein. The study was small and the article should say so: eight people with two changed SACS copies, and two parents who each carried one.

Group	Sacsin in blood cells	Health status
Two changed SACS copies (8 people)	Cut by more than 80 percent, and not detectable at all in some	Have ARSACS
One changed copy (2 carrier parents)	52 to 59 percent of control levels	Well, no symptoms
No changed copy (controls)	Normal	Well

The paper’s own abstract says the carriers “showed 50% reduction in sacsin protein levels compared to controls”. The exact measured values were 59 plus or minus 10 percent by one method and 52 plus or minus 11 percent by another. So “about half” is right, and “exactly 50 percent” is not.

Two months later a separate group published in Movement Disorders and found the same thing in a different set of people. Their test told apart four groups: people with two changed copies, healthy controls, people with other spastic ataxias, and carriers. Their published abstract gives no group sizes, so none are quoted here. Two teams, two cohorts, one result. That is what makes this a replicated finding rather than a single report.

One caution belongs in the same breath. The stated job of this test is diagnosis, and in particular sorting out variants of uncertain significance, meaning gene changes whose effect nobody has pinned down yet. It was not built to reassure carriers. The authors also wrote that the method “could not be immediately implementable for diagnostic laboratories without specialized knowledge”. A family doctor cannot order it today. If a lab report is confusing, a board-certified genetic counselor is the right person to read it out loud. Genetic counseling means a session with a certified professional who explains what a gene result does and does not mean.

Section recap: Sacsin is a huge chaperone protein, and its exact job is still being worked out. In 2024, two independent teams measured it in blood: near-zero in people with two changed copies, and about half of normal in carriers who were clinically well.

How ARSACS is inherited, and what the 23andMe report actually tested

ARSACS is passed on in an autosomal recessive pattern. That means a person needs two non-working copies of SACS, one from each biological parent, before the disease appears. One working copy makes roughly half the normal sacsin, and half runs the cell fine. The National Ataxia Foundation says it in the plainest words available. A person with one altered copy “does not develop any neurological symptoms and is called a carrier,” because “the normal SACS gene compensates”.

Not now, and not at fifty. GeneReviews states it without hedging.

The arithmetic, said out loud

If two people each carry a changed SACS copy, GeneReviews gives the odds for each pregnancy. There is “a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being neither affected nor a carrier”. Put in whole people: about 25 out of every 100 pregnancies in such couples produce a child with ARSACS.

Situation	Chance of a child with ARSACS, per pregnancy
Both parents carry a SACS variant	25 percent
One parent carries, the other does not	Effectively zero for ARSACS
One parent carries SACS, the other carries a variant in a different recessive gene	Effectively zero for ARSACS

That last row is the one that stops needless panic. Recessive risk is gene-specific. A SACS carrier paired with, say, a cystic fibrosis carrier does not face a raised ARSACS risk from that pairing. The two genes never meet.

The dice are also rolled fresh every time. A healthy first child tells you nothing about the next pregnancy.

What the consumer report covers, in the company’s own words

23andMe’s live Canadian page states the scope. The report “is indicated for the detection of one (1) variant in the SACS gene and is most relevant for people of French Canadian descent”. One variant. The same page adds the limit. “23andMe does not test for all possible genetic variants linked to ARSACS, and individuals who have zero variants detected still have a chance of being a carrier for ARSACS”. It also says its carrier reports are “not intended to tell you anything about … the health of your fetus”.

That limit is not a small one. More than 200 disease-causing SACS variants are now known, and most are missense changes, meaning single-letter swaps. MedlinePlus adds the sentence that matters most for a partner from anywhere else. “Mutations causing ARSACS in people outside of Quebec are varied and usually unique to that person or family”.

Two founder variants dominate in Quebec. The main one is written today as c.8844del, with the protein change p.(Ile2949PhefsTer4), listed in ClinVar as pathogenic. Older papers and both NIH pages still call it 6594delT, and MedlinePlus reports it in “more than 90 percent of people with ARSACS in Quebec”. The second is c.7504C>T, p.(Arg2502Ter). The live 23andMe page never names which variant it tests, so no name is claimed for it here.

There is a second blind spot, and it is written into US regulation. The FDA rule covering this product class is 21 CFR 866.5940. It defines the product as a carrier “screening” system. It also states plainly that “the device is not intended for copy number variation” testing. Whole-gene deletions are exactly the kind of change that class of test cannot see, and GeneReviews notes such deletions do occur in SACS. A negative consumer result is a lowered chance, not a zero. A genetic counselor can say what a specific report did and did not cover.

Section recap: Two changed copies cause ARSACS; one does not. The consumer report checks a single variant against a background of more than 200 known ones, and by rule cannot look for deletions at all.

The Quebec founder effect, the move to New England, and the honest number for one pregnancy

Why does a Quebec place name sit on a US test report? Because of history, and because that history is unusually well documented. A 2021 review in the Journal of Medical Genetics calls the Saguenay-Lac-Saint-Jean region “the product of a triple founder effect”. Settlers came from France in the 1600s. People then moved within Quebec, and the Saguenay itself was settled in the 1800s. Each step narrowed the pool of ancestors. A few gene changes rode along and became common.

Carrier rates, with their dates attached

Published carrier rates for the region differ, and the reason is that they were measured in different decades by different methods. Quoting one number without its date is how bad health writing happens.

Carrier rate	Group measured	Source and date
1 in 22	Charlevoix-Saguenay-Lac-Saint-Jean region	Gene discovery paper, 2000
1 in 21	Saguenay-Lac-St-Jean, from data gathered between 1941 and 1985	GeneReviews, citing Dupre 2006
1 in 18 (range 1 in 20 to 1 in 17)	Regional screening phase, 11,223 people tested	Measured 2010 to 2022
1 in 20 (range 1 in 22 to 1 in 18)	Provincial screening phase, 9,381 people tested	Measured 2010 to 2022
1 in 92 (range 1 in 59 to 1 in 152)	Quebec residents from outside the region, 1,743 tested	Measured 2010 to 2022

The 2025 report goes finer still. Around Saguenay the rate runs between 1 in 20 and 1 in 17, while near the town of Alma it runs between 1 in 17 and 1 in 13. The authors attach a warning to their own map: towns showing the highest rates often had fewer than 30 people tested, so those results “must be interpreted cautiously”. The spread is the finding. Do not average it into one tidy figure.

Birth numbers follow the same rule. GeneReviews reports that the birth incidence “was 1:1,932, but is now declining because of voluntary carrier screening,” and the past tense is theirs. MedlinePlus gives a range of 1 in 1,500 to 2,000 for the region and notes that outside Quebec the rate “is unknown”.

How the alleles reached New England

Between 1840 and 1930, an estimated 900,000 French Canadians moved to the United States for work, according to a Quebec educational history resource. They built neighbourhoods called Little Canadas in mill towns such as Lowell, Massachusetts, Manchester, New Hampshire, and Lewiston, Maine. This is a history source, not a medical one, and it is used here only to explain geography.

The genetic half of that story is measured. Among Quebec residents living outside the Saguenay region, the main founder variant still turns up at about 1 in 92. The allele already travels.

Doing the multiplication

Take a known carrier and a partner at that 1 in 92 rate. When both partners carry, each pregnancy carries a 1 in 4 chance of an affected child. The two figures multiply out to roughly 1 in 368 per pregnancy. That is arithmetic on a Quebec figure, and it is shown as an illustration only. No measured SACS carrier rate exists in this evidence set for people of Irish, German, Polish or other non-French-Canadian ancestry, so no number is invented for them here.

The useful move is not more reading. It is one test. If a partner’s full SACS sequencing is negative, the estimated risk drops to a small fraction of one percent. If it is positive, the number jumps to 25 percent per pregnancy. Those are two different conversations, and only a lab result tells you which one you are in. A genetic counselor can order the right version of that test.

Section recap: Regional carrier rates run from 1 in 22 in 2000 to a measured 1 in 18 for 2010 to 2022. Among Quebec residents from outside the region, the measured rate is about 1 in 92. Partner testing is what turns an estimate into a number.

What ARSACS does to people who have it, and on what timeline

Everything in this section describes people with two changed SACS copies. A carrier has one. The distinction is repeated on purpose, because these figures are frightening and they belong to someone else.

GeneReviews collected the core features across several cohorts, and its table carries the group sizes, which is unusual and welcome.

Feature, in people with two changed copies	Reported rate
Ataxia, meaning loss of coordinated movement	96 percent (135 of 140)
Nerve damage in the arms and legs	97 percent (36 of 37)
Stiff, tight leg muscles (spasticity)	75 percent (77 of 103)
Jerky eye movements (nystagmus)	74 percent (89 of 120)
Slurred speech, by age 18	74 percent (37 of 50)
High-arched feet	61 percent (75 of 123)
Bladder urgency	34 percent (38 of 111)
Learning or school difficulty	29 percent (28 of 95)

The nerve-damage row rests on just 37 people, so it is the shakiest number in the table.

Timeline

The mean age at onset is “approximately six years (range: 0-40 years)”. MedlinePlus is more concrete about how it starts: “Walking problems usually begin between the ages of 12 months and 18 months, as toddlers are learning to walk”. Stiffness follows in childhood and nerve damage in the teen years, though GeneReviews notes that nerve damage sometimes comes first.

Progress is measured in decades, not months, but it is real. A four-year Quebec study of 40 adults measured the pace. Walking speed fell by a mean of 0.044 metres per second each year. The distance walked in six minutes fell by 20.8 metres each year. Balance scores dropped about 1.5 points a year. The authors called this “a progression rate beyond the normal aging process”. A second study of 60 adults tracked two years of change to help design future trials, finding a 24 percent worsening on a timed walk-and-turn test.

Mobility, without the scare line

Search results often say “wheelchair by forty.” The sourced picture is softer and more varied.

• GeneReviews: 25 percent (6 of 24) were wheelchair-bound after age 30
• MedlinePlus: “Most affected individuals require wheelchair assistance by the time they are in their thirties or forties”
• A 2023 study of wheelchair users: “approximately 45% of adults with ARSACS are permanent wheelchair users”
• National Ataxia Foundation: most need a wheelchair between 30 and 40 years old

That 45 percent figure also means a majority of adults with ARSACS are not permanent wheelchair users. And in the 36 wheelchair users studied, aged 34 to 64, upper-limb strength was preserved. The authors’ conclusion was practical: offer wheelchair skills training, which “could increase their daily and social participation”.

On life span, GeneReviews chooses its words carefully. “The only study to date that reported on life expectancy in those with ARSACS concluded that it was shortened on average to 51 years”. The word “only” is theirs. The National Ataxia Foundation gives a looser 50 to 60 years.

What a neurologist looks for

ARSACS leaves unusually distinctive marks. On brain MRI, 83 percent (39 of 47) show shrinkage of the upper cerebellum. Straight dark lines appear in the pons, a structure at the base of the brain, in 49 percent (19 of 39). In the eye, 33 percent (19 of 58) show thickened myelinated retinal fibres. Most striking, a scan layer thicker than 119 micrometres at the optic nerve head gave “a sensitivity of 100% and specificity of 99.4%” for ARSACS. Most ataxias thin that layer. This one thickens it.

One more line matters for anyone reading a variant report: “No clear genotype-phenotype correlations for SACS have been identified”. Nobody can forecast a course from a variant name. Anyone with balance or gait symptoms should see a neurologist rather than reason from a gene report.

Section recap: In people with two changed copies, ataxia runs near 96 percent, nerve damage near 97 percent, and stiffness near 75 percent, with onset around age six. About 45 percent of affected adults are permanent wheelchair users. None of it describes a carrier.

Confirming a result in the US and Canada, and why a partner’s test runs on a clock

Three different tests get blurred together online. They are not the same product.

Tier	What it is	What it can and cannot do
Consumer carrier report	A screening test for a set list of variants	Flags one SACS variant; cannot diagnose; by rule not built to detect deletions
Clinical confirmation	The same finding re-run in an accredited clinical laboratory in the US, or a provincially accredited lab in Canada	Produces a result a clinician can act on and put in a chart
Partner’s expanded panel	Sequencing that reads all of SACS, not just founder spots	The test that decides whether any risk exists for a pregnancy
Diagnostic testing for symptoms	Looking for two changed copies in someone with signs	Sequencing finds about 95 percent; deletion and duplication testing covers about 5 percent

The 2024 blood sacsin test joins that last row rather than replacing it. Its published purpose is to settle variants of uncertain significance. Measuring the drop in sacsin “allows defining them as pathogenic variants,” which prediction software cannot do with confidence. It is a specialist assay, by the authors’ own account.

Why the partner’s test is the decisive one

The American College of Medical Genetics and Genomics addressed this directly in a 2021 practice resource. Carrier screening began as an ancestry-keyed exercise, checking Tay-Sachs in Ashkenazi families and sickle cell in Black patients. Cheap sequencing changed that. ACMG now recommends “a consistent and equitable approach for offering carrier screening to all individuals during pregnancy or preconception”. A single-variant, ancestry-keyed ARSACS test is a survivor of the old model. A panel that reads all of SACS is the current one.

Timing is not a detail. ACMG names the yardstick for this whole field: “Reproductive decision making is the established metric for clinical utility of population-based carrier screening”. A result that lands after a decision has passed has no clinical utility at all. During a pregnancy, that argues for contacting a genetic counselor and an obstetric provider early rather than late, and letting them set the schedule. A consumer report cannot fill that role, since 23andMe itself says its carrier reports are not intended to say anything about the health of a fetus.

Where to find the right clinician

• United States: the National Society of Genetic Counselors lists over 3,300 genetic counselors at nsgc.org/findageneticcounselor. NSGC calls it “not a referral service” but a member list, and advises checking coverage with your insurer first
• Canada: the Canadian Association of Genetic Counsellors now hosts its national directory of genetics clinics at genetic-counsellors.ca
• Specialist ataxia care: the National Ataxia Foundation runs an Ataxia Center of Excellence network and keeps an ARSACS page at ataxia.org

There is a nice detail in the US rulebook here. The FDA classifies these consumer carrier tests as Class II devices with special controls. One control requires the maker to tell buyers how to reach “a board-certified clinical molecular geneticist or equivalent” for counseling before and after the test. Calling a counselor is not an extra step. It is the regulator’s own design assumption.

Section recap: A consumer report screens, a clinical lab confirms, and a partner’s full SACS panel decides. ACMG’s own yardstick is whether results arrive in time to inform a decision.

Quebec’s public screening program: what happens when a founder population measures itself

No English-language consumer page seems to mention this, and it is the most instructive thing in the file. Quebec built a free carrier screening program for its own founder conditions, and in 2025 it published twelve years of results.

How it works, as described in that report:

• Started in 2010 in the Saguenay-Lac-Saint-Jean, Haute-Cote-Nord and Charlevoix regions, and went province-wide in 2018
• Covers four recessive conditions with local founder effects: ARSACS, Andermann syndrome, Leigh syndrome French-Canadian type, and tyrosinemia type 1
• An online module with a knowledge quiz gates informed consent, then a self-sampling kit arrives by mail
• Participants pay roughly one Canadian dollar in postage. “This is the only cost associated with participating,” and public health care covers the rest

The results, covering 2010 to 2022:

Measure	Reported figure
People tested	20,604
Carriers of at least one condition, all offered counseling	3,578
Couples where both partners carry the same condition	116, about 1.1 percent of tested pairs
Of those, ARSACS couples	38, the largest single group
Total genetic analyses run	102,935

Each of those 116 couples faces a 25 percent chance per pregnancy. The 2021 founder-effect review makes the peer-reviewed case for treating this as a model rather than a curiosity. It credits gene discovery in the region with letting public health “design precision medicine public health strategies based on carrier testing”.

Three honest limits

First, the program is residency-based. People from outside the region “are referred to the nearest genetics clinic through an established provincial partnership,” and a New Hampshire resident cannot enrol. The equivalent elsewhere is an expanded panel ordered through a counselor.

Second, the reported rates are probably low. The authors note that eligibility rests on self-reported ancestry, so “the HF reported will likely be underestimated for each condition”.

Third, and most often misreported: the program did not publish what carrier couples chose to do. The 2025 paper says so outright: “This is in line with the decision we made to not compile the reproductive decision of the carrier couples”. A 2018 interview study of 15 carrier couples looked at their experience, not their choices. Nobody should claim to know the outcomes.

What that interview study did find is worth carrying. Couples “had little knowledge about the target diseases before being identified as carriers, despite pre-test education sessions”. They “perceived themselves at low risk of being a carrier couple, whatever their family history”. And the verdict came in two parts, both true: the result “was initially a shock,” and yet “carrier couples appreciated knowing their status”. The authors’ conclusion was that post-test counseling matters most for positive results.

Section recap: Over 2010 to 2022 Quebec tested 20,604 people and found 116 carrier couples, 38 of them for ARSACS. The program is residency-based, its rates are likely underestimates, and it deliberately did not publish reproductive outcomes.

Treatment in 2026: nothing approved, care that helps, and the size problem blocking gene therapy

Most pages end with “there is no cure; research is ongoing.” That is too vague to plan around. Here is the checked version, as of 25 August 2026.

• The FDA drug label and Drugs@FDA databases return no match for an ARSACS indication
• The Health Canada Drug Product Database returns an empty result for ARSACS, sacsin and spastic ataxia
• ClinicalTrials.gov lists five ARSACS studies in total, and not one is a drug or gene-therapy trial

Those five are a rare-disease registry (NCT01793168), a wheelchair skills training study (NCT06596850), and three rehabilitation studies (NCT05479656, NCT05768750, NCT06261424). Every interventional trial on the registry is rehabilitation or wheelchair skills. GeneReviews agrees on the drug side: “Curative therapy is not available; all treatments are symptomatic”. So does a 2023 laboratory paper, which opens by noting patients have “no available treatments”.

Care that is actually offered

Supportive care is not nothing. GeneReviews lists what is used, and this list stays inside that table:

• Physiotherapy, including exercise-game training, for unsteady walking
• Physiotherapy plus oral baclofen, botulinum toxin injections and braces for stiffness, with early use possibly preventing shortened tendons and locked joints
• School support services where learning is affected
• Home-based speech therapy
• Hearing aids where hearing is affected
• Bladder medicines plus a urology referral for urgency
• Wheelchair skills training, which a 2023 study argues for and a registered trial is now testing

Two corrections to common advice belong here. Routine heart checks are often listed as standard for ARSACS. GeneReviews says the opposite. Heart problems are “apparently not a frequent part of the phenotype of ARSACS overall,” so “a special workup on a routine basis does not appear to be required”. And its whole surveillance table for people with ARSACS amounts to a complete neurological assessment once a year, plus gait, fine motor and speech checks as needed. On drugs, there is no absolute contraindication, though known nerve-toxic drugs should be used with care. A treating neurologist decides all of this, not a website.

Why gene therapy has not arrived, in one calculation

Families are often told gene therapy is “promising.” The real obstacle is arithmetic, and both numbers come from primary records.

The coding part of SACS is 13,740 base pairs long, computed from the NIH reference sequence NM_014363.6. A standard adeno-associated virus vector, the delivery shell used in most approved gene therapies, holds “~4.7 kb,” per a 2022 review of that exact problem. The gene is roughly three times too big for the truck.

So investigators are engineering around the limit: splitting genes across two vectors, or building shortened versions. The Ataxia Charlevoix-Saguenay Foundation reports funding a project that “created a smaller version of the faulty protein (called minisacsin) that can fit into a viral vector”. That is a foundation project report at preclinical stage, not a result in people.

The same caution applies to the most-quoted lab finding. In mice lacking sacsin, the antibiotic ceftriaxone “significantly improved motor performances”. The authors’ own ceiling is the important part: the work supports “further optimization in preclinical and clinical settings”. Preclinical means before people. No ceftriaxone trial for ARSACS appears on the registry.

What has genuinely advanced: readiness, not treatment

Trial infrastructure is being built. A 2024 multicentre study fitted wearable sensors to 36 people, 18 with ARSACS and 18 controls, and found 14 of 30 gait measures separated the groups strongly in the lab. Its stated aim was to prepare outcome measures “with treatment trials on the horizon”. The PROSPAX consortium published its own project report through EuroAtaxia. It describes 331 study subjects over 890 visits and 2,877 biosamples between 2020 and 2024, across ARSACS and a second condition, SPG7. Those totals come from the consortium’s summary, not from a peer-reviewed paper, and they are not 331 ARSACS patients. On the Canadian side, the natural-history work in 40 and then 60 adults exists explicitly to define “inclusion criteria and selecting COAs for future clinical trials”.

That is measuring equipment, not medicine. Saying so plainly is more useful to a family than optimism.

Section recap: As of August 2026, no ARSACS therapy is approved by the FDA or Health Canada, and all five registered studies are rehabilitation or registry work. The gene’s 13.7 kb coding sequence against a 4.7 kb vector is the concrete reason gene replacement has not arrived.

Carriers, siblings, and the law in the US and Canada

Start with the strongest sentence in the file, because carriers keep looking for it. GeneReviews: “Heterozygotes are asymptomatic and are not at risk of developing the disorder”. The 2024 blood work gave that claim a measured basis, with carriers near half of normal sacsin and clinically well.

The one contrary report, reported honestly

A 2023 case report from Korea described one person in their 50s with one changed SACS copy, late-onset ataxia and stiffness, and lowered sacsin levels. The authors titled it “May Cause Late-Onset Sacsinopathy,” and their own verbs stay hedged throughout. It is a single case, unreplicated, weighed against GeneReviews’ flat statement and two 2024 studies in which carriers were well. It is reported here rather than buried. It is not a reason to plan around.

Nor is it a reason for scans or yearly neurology visits. The GeneReviews surveillance table applies to “Individuals with ARSACS,” and no US or Canadian professional body in this evidence set recommends any monitoring for carriers. New or unexplained balance problems should still be taken to a doctor, as they would be for anyone.

Telling the family

Carrier status runs in families in a predictable way. GeneReviews notes that each sibling of an obligate carrier parent has a 50 percent chance of carrying the same variant. The same logic applies going down: each copy is passed on at random, so each child of a carrier has a 50 percent chance of inheriting the changed one.

Testing relatives one step at a time, called cascade testing, is how families work outward from one result. That matters before a sibling or an adult child plans a pregnancy. It matters much less to a healthy young child’s own health, which is why the tools here are built for adults. The FDA class defines these tests for “adults of reproductive age,” and the ACMG resource addresses pregnancy and preconception.

For the conversation itself, the Quebec interview study offers the most useful line: carriers “perceived themselves at low risk … whatever their family history”. A clean family history convinces nobody’s genes. A better script than “a spit test came back strange” is short and specific. This family carries a change in a gene called SACS. It caused no health problems here. It only matters if a partner carries a change in the same gene.

What the law protects, on each side of the border

Question	United States (GINA)	Canada (Genetic Non-Discrimination Act)
Can a health insurer use it?	No. Protections cover private health insurers, Medicare, Medicaid, Federal Employees Health Benefits and the Veterans Health Administration	No. Nobody may require a genetic test, or its results, as a condition of a contract or service
Can an employer use it?	Not at employers with 15 or more staff. Employers under 15 are not covered, and the US military “is permitted to use genetic and medical information to make employment decisions”	The ban binds “any person,” with an exception for health care practitioners and researchers
Life, disability or long-term-care insurance?	Not protected. GINA’s health protections “do not cover long-term care insurance, life insurance, or disability insurance”	Covered by the same ban. The Supreme Court’s own example: insurers “couldn’t make people get tested to get life insurance coverage”
Penalty for breaking it	Title II is enforced by the EEOC; Labor, HHS and Treasury handle Title I health-insurance rules	Criminal: fines up to $1 million, or up to five years in jail, or both
Tested in court?	Not covered in this evidence set	Upheld as constitutional in Reference re Genetic Non-Discrimination Act, 2020 SCC 17, decided 10 July 2020

The practical asymmetry is worth stating once. In the United States, a carrier result cannot be used by a large employer or a health insurer, but a life, disability or long-term-care insurer may legally ask about it. In Canada, the federal ban reaches insurance contracts head-on. Canada’s law also defines a genetic test broadly enough to include carrier testing outright.

One more practical note. Coverage of counseling and confirmatory testing varies by plan. NSGC’s own advice is to “check with your insurance company to verify coverage of genetic counseling, testing and authorized providers” before booking. A genetic counselor can also help sequence those steps sensibly.

Section recap: Carriers are unaffected, and the only contrary evidence is one unreplicated case report. GINA leaves life, disability and long-term-care insurance uncovered, while Canada’s Act covers them and carries criminal penalties.

Frequently asked questions

Will a SACS carrier develop ARSACS later in life?

The established answer is no. GeneReviews states that carriers “are asymptomatic and are not at risk of developing the disorder”. In 2024, two teams measured sacsin in blood cells and found carriers at roughly half of control levels and clinically well. One unreplicated case report proposes a late-onset carrier picture in a single person, using the word “may”. No body recommends monitoring carriers.

Will a carrier’s children inherit ARSACS?

Only if the other biological parent also carries a SACS variant. If both do, the chance is 25 percent per pregnancy, recalculated every time. If only one does, ARSACS does not occur, though each child has about a 50 percent chance of being a carrier. A partner carrying a variant in a different recessive gene adds no ARSACS risk. Partner testing is the step that produces a real number.

Can this result affect health or life insurance?

In the US, health insurance is protected by GINA, including Medicare, Medicaid, Federal Employees Health Benefits and the Veterans Health Administration. Life, disability and long-term-care insurance are not protected. In Canada, the Genetic Non-Discrimination Act bars anyone from requiring a genetic test, or its results, as a condition of a contract or service. The Supreme Court upheld that law in 2020. Coverage of testing itself is a separate question to raise with the insurer.

Can an employer find out?

Not lawfully, at most US workplaces. GINA’s employment title covers employers with 15 or more staff and is enforced by the EEOC. Employers with fewer than 15 staff fall outside it, and the US military may use genetic information in employment decisions. In Canada, the federal ban applies to any person offering goods, services or contracts, with an exception for clinicians and researchers.

Is a second opinion worth it after a consumer result?

Yes, and the regulator assumes it. The FDA rule for these devices requires makers to tell buyers how to reach “a board-certified clinical molecular geneticist or equivalent” for counseling. The report screens a single SACS variant against more than 200 known ones and cannot look for deletions. Anything driving a medical or reproductive decision should be re-run in an accredited clinical laboratory in the US or a provincially accredited Canadian lab, with a genetic counselor reading the result.

Summary

A carrier result on a consumer test names one changed copy of SACS out of two. One working copy makes about half the normal sacsin, and in 2024 two independent teams measured that half directly in blood cells and found those carriers well. Half is enough.

The clinical picture that dominates search results, ataxia near 96 percent, nerve damage near 97 percent, onset around age six, belongs to people with two changed copies. So does the mobility data, where about 45 percent of affected adults are permanent wheelchair users.

The number a carrier actually needs comes from a partner’s lab result, not from more reading. Both carrying means 25 percent per pregnancy; one carrying means effectively zero for ARSACS. The consumer report checks one variant out of more than 200 and, by regulation, is not built to detect deletions.

Quebec’s own answer to this situation was to measure it: 20,604 people tested between 2010 and 2022, 116 carrier couples found, 38 of them for ARSACS. The program is residency-based, and it never published what those couples chose to do.

Treatment in 2026 is honest and short. Nothing is approved in the US or Canada, and every registered study is rehabilitation or registry work. Gene replacement is blocked by a 13.7 kb gene facing a 4.7 kb delivery shell. Supportive care is real and worth having. The next step for a carrier is a genetic counselor, not another search result.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. Vermeer S, van de Warrenburg BP, Kamsteeg EJ, Brais B, Synofzik M. ARSACS. GeneReviews, University of Washington / NCBI Bookshelf NBK1255. Initial posting 9 December 2003; last update 2 January 2020; page verified 2026-08-25. https://www.ncbi.nlm.nih.gov/books/NBK1255/
2. De Ritis D, Ferre L, De Winter J, Tremblay-Desbiens C, Blais M, Bassi MT, et al. (2024). Reduction of sacsin levels in peripheral blood mononuclear cells as a diagnostic tool for spastic ataxia of Charlevoix-Saguenay. Brain Communications 6(4):fcae243 (epub 18 July 2024). PMID 39091421. DOI 10.1093/braincomms/fcae243. https://pubmed.ncbi.nlm.nih.gov/39091421/
3. Tunca C, Islek Camadan EE, Smolina N, Palvadeau RJ, Oztop Cakmak O, Vural A, et al. (2024). Sacsin levels in PBMCs: A diagnostic assay for SACS variants in peripheral blood cells – A PROSPAX study. Movement Disorders 39(12):2291-2297 (epub 24 September 2024). PMID 39314081. DOI 10.1002/mds.30012. https://pubmed.ncbi.nlm.nih.gov/39314081/
4. Beichert L, Ilg W, Kessler C, Traschutz A, Reich S, Santorelli FM, et al. (2024). Digital Gait Outcomes for Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS): Discriminative, Convergent, and Ecological Validity in a Multicenter Study (PROSPAX). Movement Disorders 39(9):1544-1555. PMID 38847438. DOI 10.1002/mds.29876 – with the PROSPAX consortium project summary published via EuroAtaxia (331 subjects, 890 visits, 2,877 biosamples, 2020-2024, ARSACS and SPG7), retrieved 2026-08-25. https://pubmed.ncbi.nlm.nih.gov/38847438/
5. Fortin CA, Cote-Richer M, Truchon K, Leblanc J, Pratte A, Tardif J, et al. (2025). Successes of an innovative population-based carrier screening program for 4 prevalent recessive hereditary diseases in a population with a founder effect in Quebec, Canada. Genetics in Medicine Open 3:103435 (epub 9 May 2025). PMID 40584454. DOI 10.1016/j.gimo.2025.103435. https://pubmed.ncbi.nlm.nih.gov/40584454/
6. Bchetnia M, Bouchard L, Mathieu J, Campeau PM, Morin C, Brisson D, et al. (2021). Genetic burden linked to founder effects in Saguenay-Lac-Saint-Jean illustrates the importance of genetic screening test availability. Journal of Medical Genetics 58(10):653-665. PMID 33910931. DOI 10.1136/jmedgenet-2021-107809. https://pubmed.ncbi.nlm.nih.gov/33910931/
7. Engert JC, Berube P, Mercier J, Dore C, Lepage P, Ge B, et al. (2000). ARSACS, a spastic ataxia common in northeastern Quebec, is caused by mutations in a new gene encoding an 11.5-kb ORF. Nature Genetics 24(2):120-125. PMID 10655055. DOI 10.1038/72769. https://pubmed.ncbi.nlm.nih.gov/10655055/
8. US National Library of Medicine, National Institutes of Health. MedlinePlus Genetics: “Autosomal recessive spastic ataxia of Charlevoix-Saguenay” condition page and “SACS gene” page. Both retrieved live 2026-08-25. https://medlineplus.gov/genetics/condition/autosomal-recessive-spastic-ataxia-of-charlevoix-saguenay/
9. National Center for Biotechnology Information (NIH), Gene ID 26278 “sacsin molecular chaperone”, RefSeq NM_014363.6 / NP_055178.3 (GenBank record dated 2026-02-02; CDS 590..14329 = 13,740 bp), and UniProtKB Q9NZJ4 (4,579 amino acids; 521,126 Da). Queried live 2026-08-25. https://www.ncbi.nlm.nih.gov/gene/26278
10. Marrone L, Marchi PM, Azzouz M (2022). Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders. Expert Opinion on Biological Therapy 22(9). PMID 34904932. DOI 10.1080/14712598.2022.2012148. https://pubmed.ncbi.nlm.nih.gov/34904932/
11. Bagaria J, Bagyinszky E, An SSA (2022). Genetics of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) and Role of Sacsin in Neurodegeneration. International Journal of Molecular Sciences 23(1):552. PMID 35008978. DOI 10.3390/ijms23010552. https://pubmed.ncbi.nlm.nih.gov/35008978/
12. Del Bondio A, Longo F, De Ritis D, Spirito E, Podini P, Brais B, et al. (2023). Restoring calcium homeostasis in Purkinje cells arrests neurodegeneration and neuroinflammation in the ARSACS mouse model. JCI Insight 8(12). PMID 37159335. DOI 10.1172/jci.insight.163576. https://pubmed.ncbi.nlm.nih.gov/37159335/
13. Lessard I, Cote I, St-Gelais R, Cote L, Mathieu J, Gagnon C, et al. (2024). Natural History of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay: a 4-Year Longitudinal Study. The Cerebellum. PMID 37101017. DOI 10.1007/s12311-023-01558-w – with Lessard I, Duchesne E, Hebert LJ, et al. (2025). Selection of Clinical Outcome Assessments for Trial Readiness in ARSACS, Part 2. The Cerebellum. PMID 40332679. DOI 10.1007/s12311-025-01849-4. https://pubmed.ncbi.nlm.nih.gov/37101017/
14. Bourassa J, Routhier F, Gagnon C, et al. (2023). Wheelchair mobility, motor performance and participation of adult wheelchair users with ARSACS: a cross-sectional study. Disability and Rehabilitation: Assistive Technology 18(4). PMID 33307884. DOI 10.1080/17483107.2020.1858195. https://pubmed.ncbi.nlm.nih.gov/33307884/
15. Gregg AR, Aarabi M, Klugman S, Leach NT, Bashford MT, Goldwaser T, et al.; ACMG Professional Practice and Guidelines Committee (2021). Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics. Genetics in Medicine 23(10):1793-1806. PMID 34285390. DOI 10.1038/s41436-021-01203-z. https://pubmed.ncbi.nlm.nih.gov/34285390/
16. Regulatory and trial status of ARSACS therapy in the US and Canada, verified by live query on 2026-08-25: openFDA drug label and Drugs@FDA APIs (no ARSACS indication), Health Canada Drug Product Database API (no product), ClinicalTrials.gov API v2 (five studies: NCT01793168, NCT06596850, NCT05479656, NCT05768750, NCT06261424, all registry or rehabilitation), and 21 CFR 866.5940 via eCFR (title 21 current as of 2026-08-21). https://www.ecfr.gov/current/title-21/part-866/section-866.5940
17. 23andMe. ARSACS Carrier Status report – product scope and limitations as stated by the manufacturer (company material, retrieved live 2026-08-25). https://www.23andme.com/en-ca/topics/carrier/arsacs/
18. US National Human Genome Research Institute (NIH), Genetic Discrimination and the Genetic Information Nondiscrimination Act of 2008, with the US Equal Employment Opportunity Commission GINA Title II pages. Both retrieved live 2026-08-25. https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination
19. Department of Justice Canada, Genetic Non-Discrimination Act, S.C. 2017, c. 3 (assented 4 May 2017; consolidation current to 2026-06-21), with the Supreme Court of Canada, Reference re Genetic Non-Discrimination Act, 2020 SCC 17 (decided 10 July 2020, docket 38478). https://laws-lois.justice.gc.ca/eng/acts/G-2.5/page-1.html
20. Tardif J, Pratte A, Laberge AM (2018). Experience of carrier couples identified through a population-based carrier screening pilot program for four founder autosomal recessive diseases in Saguenay-Lac-Saint-Jean. Prenatal Diagnosis 38(1):67-74. PMID 28419508. DOI 10.1002/pd.5055. https://pubmed.ncbi.nlm.nih.gov/28419508/
21. Kim S, Ryoo N, Park YH, Bagyinszky E, An SSA (2023). A Novel Mutation in Sacsin, p.Val1335Ile, May Cause Late-Onset Sacsinopathy Due to Haploinsufficiency. Current Issues in Molecular Biology 45(12). PMID 38132465. DOI 10.3390/cimb45120619. https://pubmed.ncbi.nlm.nih.gov/38132465/
22. Referral routes and patient-organisation resources, all URLs probed live 2026-08-25: National Society of Genetic Counselors, Find a Genetic Counselor (https://www.nsgc.org/findageneticcounselor); Canadian Association of Genetic Counsellors public directory (https://genetic-counsellors.ca/); National Ataxia Foundation ARSACS page and Ataxia Center of Excellence network (https://www.ataxia.org/arsacs/); Ataxia Charlevoix-Saguenay Foundation research pages, source of the preclinical “minisacsin” programme (https://arsacs.com/).
23. LEARN Quebec Secondary History resource. French Canadian migration to New England, 1840-1930 (educational source; the 900,000 figure is an estimate). Retrieved live 2026-08-25. https://secondaryhistory.learnquebec.ca/1840-1896/french-canadian-migration

Last updated: 2026-08-25

Author: Yu Mizuno (Editor-in-Chief, non-physician), GeneLumen editorial team. This article aggregates 23 sources from peer-reviewed medical literature and public health agencies (tier 1=14 / tier 2=7 / tier 3=1 / tier 4=1), including NIH resources (MedlinePlus Genetics, NCBI Gene and RefSeq, NHGRI), GeneReviews, the FDA and eCFR, Health Canada, ClinicalTrials.gov, ACMG practice resources, Canadian federal statute and Supreme Court sources, and PubMed-indexed publications. Editorial lead: Yu Mizuno, a non-physician research editor.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911.

Related: Neurogenetic Diseases category

🇯🇵 For readers in Japan — a separate Japanese edition written for Japan’s healthcare system (not a translation): ARSACS (SACS 遺伝子) の保因者と出たら｜発症する確率と日本での相談先を研究データで整理